11 results
The aim of this study is to determine whether the addition of adenosine to standard intermittent warm blood cardioplegia reduces the 6-hours post-operative cTnT in patients scheduled for minimally invasive, port access operations (mitral valve…
This study aims to gain insight in the in the level of fibrinolysis in patients with traumatic brain injury in the first 24 hours following trauma.Primairy objective:- To determine the 24-hour prevalence and course of fibrinolysis in patients with…
Our research group recently found that almost 50% of all OHCA patients develop hyperfibrinolysis, and found an interesting association between the degree of hyperfibrinolysis and hypoperfusion. Hypoperfusion was determined by base excess (BE),…
The objective of this study is to increase our understanding of the relationship between various parameters of functional lesion severity, to optimize adenosine-free evaluation of functional lesion severity.
Although these products have been used extensively in patients, the effect of these medications on experimental pain sensation has never been investigated. There is little knowledge about any direct effect of these medications on pain perception. In…
To study the impact on intra-arterial ATP infusion on Annexin A5 targeting.
This study is designed to investigate the limiting effect on infarct size of high dose intravenous adenosine during primary angioplasty
Primary Objective:* To evaluate ORR of avelumab in combination with talazoparib, in patients with locally advanced or metastatic solid tumors harboring BRCA1, BRCA2 or ATM defect.Secondary Objective:* To assess the overall safety and tolerability of…
Primary objectiveTo demonstrate that talazoparib in combination with enzalutamide is superior to placebo in combination with enzalutamide in prolonging investigator--assessed Radiographic Progression-free Survival (rPFS), in participants with mCSPC…
PrimaryTo evaluate the efficacy of single agent talazoparib in DNA damage repair (DDR) + metastatic CRPC, as measured by best objective responserate (ORR).Secondary:To evaluate efficacy with respect to the following parameters:• Time to objective…
To prove that the RECAP test has the potential of selecting patients who are sensitive to treatment with the PARP inhibitor talazoparib as measured by the PFS rate at 4 months.